Clinical Trials Browser

INDUSTRY × Hodgkin Disease × cemiplimab × Clear all

NCT04373083 2021-01-15

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Phase 2 Withdrawn

Hodgkin Disease